Back to Trial

Oracle Runs

Oracle findings and outcome history for A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity (NCT06037252).

Runs
6
Findings
6
Latest Run
Apr 6, 2026, 2:57 PM
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)

Will the results be positive?

Trial NCT06037252 is active not recruiting with primary completion January 2026. No public results, topline readout, or efficacy data found in searches or ClinicalTrials.gov. Ongoing, no evidence of positive/negative readout.

Found Apr 6, 2026, 2:57 PMReviewed Apr 6, 2026, 3:00 PM
Web Searchclinicaltrials.gov
ClinicalTrials.gov: NCT06037252 Study Record
Status: Active, not recruiting. Primary completion: 2026-01-08. No results posted or released.
Web Searchinvestor.lilly.comAug 5, 2025, 12:00 AM
Lilly Q2 2025 Earnings Presentation
Lists NCT06037252 as Phase 2 trial in Type 2 Diabetes and Obesity, primary completion Jan 2026, Oct 2026 study completion. No results mentioned.
NO_DECISIONDismissed90% confidenceGrok 4.20 (xAI)

Will the results be positive?

Trial (NCT06037252) is Phase 2, active not recruiting, with primary completion in Jan 2026. No results, readouts, or public efficacy data found. All sources confirm ongoing status; positive tirzepatide references are to other trials (e.g., SURMOUNT-2 Phase 3).

Found Apr 6, 2026, 2:08 PMReviewed Apr 6, 2026, 2:23 PM
Web Searchclinicaltrials.gov
NCT06037252 | A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
Current status: Active Not Recruiting. Estimated Primary Completion: 2026-01-08. No results posted. Primary endpoint: Percent change in body weight at Week 44.
Web Searchtrials.lilly.com
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
Trial ongoing through 2026. No efficacy results or readout reported. Focuses on safety and efficacy of investigational doses with metformin.
NO_DECISIONDismissed90% confidencemanual-chat-review

Will the results be positive?

ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.

Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:33 PM
ClinicalTrialsclinicaltrials.govMar 23, 2026, 12:00 AM
Study Details | NCT06037252 | ClinicalTrials.gov
ClinicalTrials.gov lists active not recruiting; primary completion 2026-01-08; hasResults=false on the latest posted update.
NO_DECISIONDismissed95% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No exact trial-specific public efficacy readout was found. ClinicalTrials.gov still shows this study with no posted results, and the sponsor pipeline document lists the Phase 2 trial and timing but does not report outcomes or frame it as positive/negative.

Found Apr 3, 2026, 5:20 PMReviewed Apr 3, 2026, 5:20 PM
ClinicalTrialsclinicaltrials.gov
Study Details | NCT06037252 | A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
ClinicalTrials.gov entry for NCT06037252 shows: “Study Details … No Results Posted,” indicating no public trial-specific results are available there.
Sponsorinvestor.lilly.com
Eli Lilly and Company investor presentation (Select Trials – Tirzepatide)
Lilly’s pipeline slide lists NCT06037252 as a Phase 2 diabetes trial with body-weight primary outcome and completion timing, but provides no efficacy readout or positive/negative interpretation.
NO_DECISIONDismissed97% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No trial-specific public efficacy readout was found. ClinicalTrials.gov still shows NCT06037252 as active/not recruiting with no results posted, and Lilly’s pipeline materials list the study with Jan 2026 primary completion and Oct 2026 study completion rather than reported data. That is insufficient to call positive or negative.

Found Apr 2, 2026, 5:15 PMReviewed Apr 3, 2026, 4:48 PM
ClinicalTrialsclinicaltrials.govMay 30, 2025, 12:00 AM
Study Details | NCT06037252 | A Study of Investigational Tirzepatide Doses in Participants With Type 2 Diabetes and Obesity
ClinicalTrials.gov shows NCT06037252 as 'Active, not recruiting' with 'No Results Posted.' It lists estimated primary completion in Jan 2026 and study completion in Oct 2026.
Sponsorinvestor.lilly.com
Eli Lilly 2025 Q1 Earnings Presentation
Lilly’s pipeline table lists NCT06037252 as a Phase 2 tirzepatide study in type 2 diabetes with obesity, primary outcome percent change from baseline in body weight, primary completion Jan 2026, completion Oct 2026.
NO_DECISIONDismissed96% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No trial-specific public efficacy readout was found. The cited sources indicate NCT06037252 is still ongoing/active and had future reporting timelines, so evidence is incomplete rather than positive or negative.

Found Mar 31, 2026, 9:49 PMReviewed Apr 1, 2026, 6:36 PM
ClinicalTrialsclinicaltrials.gov
Study Details | NCT06037252 | A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
ClinicalTrials.gov lists this Phase 2 tirzepatide study and notes study records and reported results are reviewed before posting; no posted results/readout were identified for this trial.
Web Searchfdaaa.trialstracker.net
NCT06037252: An ongoing trial by Eli Lilly and Company
FDAAA TrialTracker labels NCT06037252 as an ongoing trial, with results status 'Ongoing' and required reporting due Jan. 31, 2027, indicating no public results are due/read out yet.
Sponsorinvestor.lilly.com
Eli Lilly and Company investor presentation
Lilly's pipeline slide lists NCT06037252 as Phase 2 with primary completion/completion still in the future at the time of the presentation, supporting that this exact trial had not yet publicly read out.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

No oracle outcome history is available for this trial yet.